Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals

AIDS

Volumn 32, Issue 8, 2018, Pages 1007-1015

  Mora Peris, Borja ^a   Bouliotis, George ^b   Ranjababu, Kulasegaram ^c   Clarke, Amanda ^d   Post, Frank A ^e   Nelson, Mark ^a,f   Burgess, Laura ^b   Tiraboschi, Juan ^c   Khoo, Saye ^g   Taylor, Steve ^h   Ashby, Deborah ^b   Winston, Alan ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UK   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

antiretroviral therapy; cerebrospinal fluid; cognitive function; HIV; magnetic resonance spectroscopy; naive

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; CHOLINE; CREATINE; CREATININE; DARUNAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INOSITOL; LAMIVUDINE; MARAVIROC; N ACETYLASPARTIC ACID; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BRAIN; BRAIN FUNCTION; CAUCASIAN; CD4+ T LYMPHOCYTE; CELL COUNT; CEREBROSPINAL FLUID; COGNITION; COGNITIVE FUNCTION TEST; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAY MATTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; BRAIN CHEMISTRY; CLINICAL TRIAL; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN CHEMISTRY; FEMALE; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARAVIROC; TREATMENT OUTCOME;

EID: 85046817717     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001786     Document Type: Article

References (29)

1. Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol 2014; 13:1139-1151.
2. Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS 2014; 29: 253-261.
3. Schouten J, Su T,Wit FW, Kootstra NA, Caan MW, Geurtsen GJ, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS 2016; 30:1027-1038.
4. Yilmaz A, Watson V, Else L, Gisslen M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23:2537-2540.
5. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55:606-609.
6. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81.
7. Proudfoot AE, Power CA, Schwarz MK. Antichemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010; 19:345-355.
8. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2):1-85.
9. Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014; 28:131-145.
10. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76:1403-1409.
11. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
12. Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, et al. Pharmacokinetic profile and safety of 150mg of maraviroc dosed with 800/100mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J Antimicrob Chemother 2013; 68:1348-1353.
13. Foster C, Kaye S, Smith C, Mackie NE. HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study. J Virus Erad 2015; 1:173-178.
14. Overton ET, Kauwe JS, Paul R, Tashima K, Tate DF, Patel P, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav 2011; 15:1902-1909.
15. Scott J, Underwood J, Garvey LJ, Mora-Peris B, Winston A. A comparison of two postprocessing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease. Br J Radiol 2016; 89:20150979.
16. Mora-Peris B, Watson V, Vera JH, Weston R, Waldman AD, Kaye S, et al. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. J Antimicrob Chemother 2014; 69:1642-1647.
17. Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, Back D. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1455-1465.
18. Mora-Peris B, Winston A, Garvey L, Else LJ, Shattock RJ, Herrera C. HIV-1 CNS in vitro infectivity models based on clinical CSF samples. J Antimicrob Chemother 2016; 71:235-243.
19. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920-929.
20. Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, et al. Baseline CD4(R) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients. Antivir Ther 2015; 20:433-440.
21. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIVpositive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
22. Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, et al. Neurological response to cART vs. cART plus integrase inhibitor and CCR5 antagonist initiated during acute HIV. PLoS One 2015; 10:e0142600.
23. Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, et al. Neurocognition with maraviroc compared with tenofovir in HIV. AIDS 2016; 30:2315-2321.
24. Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 1993; 188:119-124.
25. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al., INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.
26. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012; 18:388-399.
27. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009; 23:83-87.
28. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS 2012; 26:1529-1533.
29. Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 2016; 30:591-600.